Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) today reported positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The outcomes met or exceeded predefined benchmarks for safety, lens delivery, and distance visual performance, representing a key clinical de-risking milestone as the company advances toward subsequent study phases.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250 — levels consistent with legal blindness. Post-implantation outcomes demonstrated meaningful improvements in everyday vision. Dr. Rafael Vázquez, principal investigator of the trial, stated that patients who were classified as legally blind can now read, enjoy everyday life activities, and drive. The impact on their independence and sense of freedom has been remarkable.
Dean Burns, President and CEO of Ocumetics, expressed full confidence in the accommodating intraocular lens technology following a detailed review of the data with Dr. Vasquez. Based on the success, planning for Group 2 surgeries is underway, with refinements already implemented to the lens delivery mechanism and multiple lens optimization initiatives aimed at enhancing outcomes.
The company is applying a rapid “win-learn” R&D approach, incorporating surgeon feedback in real time. Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation.
Ocumetics will host an exclusive webinar on Wednesday, February 4, 2026 at 4:00 PM ET to discuss the three-month study results and important updates on its first-in-human study. More information is available at www.ocumetics.com/webinar.
The company is a Canadian research and product development company dedicated to developing advanced vision correction solutions. Its intraocular lens is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses by allowing the eye’s natural muscle activity to shift focus from distance to near.
